Daratumumab-lenalidomide maintenance significantly increases MRD-negative conversion and reduces progression risk in multiple myeloma, with consistent efficacy across age, race, and risk groups.
Adding daratumumab to lenalidomide maintenance therapy after transplant in patients with multiple myeloma triples the minimal residual disease (MRD)–negative conversion rate to 50.5% vs 18.8% with ...
Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of hepatitis B virus (HBV) DNA, with significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results